Citations

Showing 10 of 108152 citations.

Multimorbidity, functional limitations, and outcomes: Interactions in a population-based cohort of older adults
Chamberlain, Alanna M. , Jacobson, Debra J., Fan, Chun , Wilson, Patrick M. , Rocca, Walter A. , Roger, Véronique L. , St Sauver, Jennifer L, Chamberlain, Alanna M , Rutten, Lila J. Finney , Sauver, Jennifer L. St.

Mayo Clinic

Journal of Comorbidity | September 9, 2019 | Volume: 9 | Issue: No issue available | Pages: No page available

10.1177/2235042x19873486 | PMID 31523633 Get It

Objective: To understand the interaction of multimorbidity and functional limitations in determining health-care utilization and survival in older adults. Methods: Olmsted County, Minnesota, residents aged 60–89 years in 2005 were categorized into four cohorts based on the presence or absence of multimorbidity (≥3 chronic conditions from a list of 18) and functional limitations (≥1 limitation in an activity of daily living from a list of 9), and were followed through December 31, 2016. Andersen–Gill and Cox regression estimated hazard ratios (HRs) for emergency department (ED) visits, hospitalizations, and death using persons with neither multimorbidity nor functional limitations as the reference (interaction analyses). Results: Among 13,145 persons, 34% had neither multimorbidity nor functional limitations, 44% had multimorbidity only, 4% had functional limitations only, and 18% had both. Over a median follow-up of 11 years, 5906 ED visits, 2654 hospitalizations, and 4559 deaths occurred. Synergistic interactions on an additive scale of multimorbidity and functional limitations were observed for all outcomes; however, the magnitude of the interactions decreased with advancing age. The HR (95% confidence interval) for death among persons with both multimorbidity and functional limitations was 5.34 (4.40–6.47) at age 60–69, 4.16 (3.59–4.83) at age 70–79, and 2.86 (2.45–3.35) at age 80–89 years. Conclusion: The risk of ED visits, hospitalizations, and death among persons with both multimorbidity and functional limitations is greater than additive. The magnitude of the interaction was strongest for the youngest age group, highlighting the importance of interventions to prevent and effectively manage multimorbidity and functional limitations early in life.
The Mary Walker Effect: Mary Broadfoot Walker
McCarter, Stuart J. , Burkholder, David B. , Klaas, James P. , Martinez‐Thompson, Jennifer M. , Boes, Christopher J. , Burkholder, David B , McCarter, Stuart J

Mayo Clinic

Journal of the Royal College of Physicians of Edinburgh | September 9, 2019 | Volume: 49 | Issue: 3 | Pages: 255-259

10.4997/jrcpe.2019.317 | PMID 31497797 Get It

Mary Broadfoot Walker (1888-1974) was the first to demonstrate the ‘Mary Walker effect’ describing the weakness of other muscle groups following release of the arteriovenous occlusion of an unrelated exercising muscle group in patients with myasthenia gravis, which led to the search for a circulating causative agent for myasthenia gravis. She was the first to clearly demonstrate that strength temporarily improved in patients with myasthenia gravis with physostigmine or Prostigmin (neostigmine). This dramatic treatment response has been erroneously termed the ‘Mary Walker effect'. Further, she noted hypokalaemia during attacks of weakness in familial periodic paralysis, pioneering treatment with potassium chloride. Although Mary Walker practiced in a nonacademic setting and trained at a time when women were not allowed to train alongside men, she was the first to convincingly demonstrate three life-changing treatments in the field of neuromuscular medicine, a feat that few physicians of any era can claim.
Myeloid Sarcoma With CBFB-MYH11 Fusion (inv(16) or t(16;16)) Prevails in the Abdomen
Dalland, Joanna , Meyer, Reid G., Reichard, Kaaren K. , Meyer, Reid, Dalland, Joanna C , Ketterling, Rhett P.

Mayo Clinic

American Journal of Clinical Pathology | September 9, 2019 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1093/ajcp/aqz168 | PMID 31671434 Get It

AbstractObjectivesMyeloid sarcoma with CBFB-MYH11 fusion may be enriched in abdominal sites. The clinicopathologic features of 11 cases are reported.MethodsWe collected clinical features, morphology, immunophenotype, and bone marrow (BM) involvement of myeloid sarcoma cases with CBFB-MYH11 fusion.ResultsEleven of 29 total myeloid sarcoma cases were CBFB-MYH11 positive and all 11 involved abdominal sites. The blastic infiltrate was associated with eosinophils in four of 11 cases and plasmacytoid dendritic cell (pDC) nodules in four of six cases. CD34, CD117, and myeloperoxidase were expressed in eight of nine, 10 of 10, and 10 of 10 cases, respectively. Ten of 10 cases showed no BM involvement.ConclusionsOur current series, combined with a literature review, identifies a compelling series of 31 (94%) of 33 cases of myeloid sarcoma with CBFB-MYH11 fusion showing a marked predilection for abdominal sites. In addition, the lack of obvious associated eosinophils, presence of pDC nodules, and lack of concurrent BM involvement suggest that “myeloid sarcoma with CBFB-MYH11 fusion” may represent a unique phenomenon.
Pan-TRK Immunohistochemistry
Harrison, Beth , Fowler, Elizabeth , Krings, Gregor , Chen, Yunn-Yi, Bean, Gregory R. , Fuhrmann, Laetitia , Barnick, Sandra E., Chen, Beiyun, Hosfield, Elizabeth M., Schnitt, Stuart J. , Fowler, Elizabeth, Chen, Yunn‐Yi , Vincent‐Salomon, Anne , Hornick, Jason L.

Mayo Clinic

American Journal of Surgical Pathology | September 9, 2019 | Volume: 43 | Issue: 12 | Pages: 1693-1700

10.1097/pas.0000000000001366 | PMID 31498178 Get It

Secretory carcinoma is a special-type breast carcinoma underpinned by a recurrent t(12;15)(p13;q25) translocation resulting in ETV6-NTRK3 gene fusion. Immunohistochemistry (IHC) using a pan-TRK antibody has been recently shown to help identify NTRK rearrangements in other tumor types. The purpose of this study was to assess the diagnostic utility of pan-TRK IHC in secretory carcinoma of the breast. Pan-TRK IHC was performed using a rabbit monoclonal antibody on whole sections of 24 breast secretory carcinomas and tissue microarray sections of other breast carcinoma types (n=203) and histologic mimics (n=15). Cases were assessed for staining intensity and localization. The 24 patients with secretory carcinoma had a median age of 44 years and a median tumor size of 1.0 cm. ETV6 fluorescence in situ hybridization was positive in all cases tested (n=20). Twenty-three cases (95.8%) showed staining with pan-TRK, which was exclusively nuclear in 19, primarily nuclear with weak cytoplasmic staining in 3, and primarily cytoplasmic with focal nuclear staining in 1. The nuclear staining was diffuse in 17 and at least focally strong in 17. The only pan-TRK negative case was a core biopsy with limited tumor. Among the 203 nonsecretory carcinomas, 21 (10.3%) showed focal, weak nuclear staining in <5% of tumor cells and 1 (0.5%) showed focal membranous staining. All histologic mimics were negative. In conclusion, diffuse and/or at least focally strong nuclear pan-TRK staining is a sensitive and specific marker for secretory carcinoma of the breast.
Budesonide Oral Suspension Significantly Improves Eosinophilic Esophagitis Histology Scoring System Results
Dellon, Evan S. , Katzka, David A. , Hirano, Ikuo , Williams, J. E. , Lan, Lan, Collins, Margaret H.

Mayo Clinic

American Journal of Surgical Pathology | September 9, 2019 | Volume: 43 | Issue: 11 | Pages: 1501-1509

10.1097/pas.0000000000001361 | PMID 31498177 Get It

Budesonide oral suspension (BOS) is a novel topical corticosteroid, which has been shown to improve symptoms and endoscopic appearance, and reduce peak eosinophil counts in patients with eosinophilic esophagitis (EoE). This trial evaluated the effect of BOS or placebo on the severity (grade) and extent (stage) of 8 histopathologic features observed in EoE, using the validated eosinophilic esophagitis histologic scoring system (EoE HSS). Patients with EoE aged 11 to 40 years with dysphagia were randomized to receive either BOS (2.0 mg twice daily) or placebo for 12 weeks. Mean (SD) EoE HSS grade and stage total scores at baseline for placebo and BOS groups were: grade, 0.42 (0.16) and 0.49 (0.14), respectively; stage: 0.38 (0.14) and 0.46 (0.11), respectively. These scores significantly decreased (improved) from baseline for patients receiving BOS versus placebo (grade: least squares mean change [SE]: placebo vs. BOS, −0.04 [0.03] vs. −0.24 [0.02]; P<0.0001; stage: −0.01 [0.02] vs. −0.19 [0.02]; P<0.0001). EoE HSS total scores improved for 6 of the 8 and 5 of the 8 histopathologic features for grade and stage, respectively, versus placebo. Change in EoE HSS total scores correlated moderately but significantly with change in endoscopic severity (endoscopic reference score; grade: R=0.5349; stage: R=0.5416; both P<0.0001). Change in EoE HSS stage total score correlated weakly with change in Dysphagia Symptom Questionnaire scores (grade: R=0.1925; P=0.0740; stage: R=0.2135; P=0.0471). These data demonstrate that the EoE HSS is a valuable endpoint of treatment response in randomized clinical trials and should be considered for future trials for EoE.
S12-14 SESSION 12: FACIOCRANIOSYNOSTOSIS – PART II THE CLASSIFICATION OF APERT SYNDROME, BASED ON CRANIAL VAULT SUTURE SYNOSTOSIS ------DIFFERENT CRANIAL BASE ANGULATIONS AND AIRWAY COMPROMISE
Cabrejo, Raysa, Wilson, Alexander T. , Steinbacher, Derek M., Alperovich, Michael , Persing, John A. , Lu, Xiaona , Sawh‐Martinez, Rajendra , Forte, Antonio J. , Wu, Rui , Alonso, Nivaldo

Mayo Clinic

Plastic and Reconstructive Surgery - Global Open | September 9, 2019 | Volume: 7 | Issue: 8S-2 | Pages: 158-159

10.1097/01.gox.0000583732.74167.01 Get It

S8B-04 SESSION 8B: FACE RESEARCH - PART I ANALYSIS OF DIFFERENTIAL EXCURSION OF THE TEMPORALIS MUSCLE AND TENDON INSERTION ON THE CORONOID PROCESS: IMPLICATIONS IN LABBE PROCEDURE
Suchyta, Marissa , Gibreel, Waleed , Mardini, Samir

Mayo Clinic

Plastic and Reconstructive Surgery - Global Open | September 9, 2019 | Volume: 7 | Issue: 8S-2 | Pages: 131-132

10.1097/01.gox.0000583564.80160.ee Get It

S8B-02 SESSION 8B: FACE RESEARCH - PART I TOWARD AN OBJECTIVE OUTCOME IN FACIAL REANIMATION SURGERY: AN EYETRACKING STUDY
Boonipat, Thanapoom , Stotland, Mitchell A. , Abu‐Ghname, Amjed , Mardini, Samir

Mayo Clinic

Plastic and Reconstructive Surgery - Global Open | September 9, 2019 | Volume: 7 | Issue: 8S-2 | Pages: 130-131

10.1097/01.gox.0000583556.90463.7d Get It

S8B-01 SESSION 8B: FACE RESEARCH - PART I USING ARTIFICIAL INTELLIGENCE TO QUANTIFY FACIAL EXPRESSION OF EMOTION: A NOVEL APPROACH TO EVALUATING OUTCOME FOLLOWING FACIAL REANIMATION SURGERY
Boonipat, Thanapoom , Lin, Jianhui , Glass, Graeme E. , Stotland, Mitchell A. , Asaad, Malke , Lin, J., Mardini, Samir , Abu‐Ghname, Amjed

Mayo Clinic

Plastic and Reconstructive Surgery - Global Open | September 9, 2019 | Volume: 7 | Issue: 8S-2 | Pages: 130-130

10.1097/01.gox.0000583552.82839.3b Get It

S6B-13 SESSION 6B: HFM ROBIN - PART I TRANS-FACIAL MINIMAL-DISSECTION MANDIBULAR DISTRACTION OSTEOGENESIS FOR NEONATAL AIRWAY OBSTRUCTION FROM PIERRE ROBIN SEQUENCE
Massary, Dominic, Lor, Lyfong S., Pan, Brian S. , Gordon, Christopher B., Elhadi-Babiker, Haithem, Runyan, Christopher Michael , Oliver, Jeremie D.

Mayo Clinic

Plastic and Reconstructive Surgery - Global Open | September 9, 2019 | Volume: 7 | Issue: 8S-2 | Pages: 119-120

10.1097/01.gox.0000583484.12441.e3 Get It